1.Gender equality in Japanese medicine
Kosuke Yasukawa ; Kyoko Nomura
Medical Education 2014;45(4):275-283
Although the problem of improving the retention rate of female physicians in Japan has been vigorously discussed, a more comprehensive discussion on gender equality has been lacking. This paper provides an overview of gender inequality in Japanese medicine and discusses measures to promote gender equality. The main causes of gender inequality include gender stereotype, bias, discrimination, women’s double burden of paid and domestic work, and a working system of long and irregular hours based on the gender division of labor. Measures to promote gender equality are necessary to create a working environment that does not disadvantage female physicians.
2.The division of labor by sex among Japanese physicians
Kosuke Yasukawa ; Kyoko Nomura
Medical Education 2012;43(4):315-319
1)To evaluate the division of labor by sex among Japanese physicians, we used anonymous, voluntary questionnaires to survey the alumni of a private medical school about the time spent weekly on clinical activities and unpaid domestic work.
2)Although the median time spent per week on clinical activities was less for women physicians (40 hours) than for men (50 hours), the time spent on unpaid domestic work was significantly more for women (30 hours) than for men (3 hours).
3)When the time spent on both clinical activities and domestic activities was totaled, women physicians worked more hours per week than did men physicians.
4)Our study showed a division of labor by sex among Japanese physicians.
3.An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
Muneaki SHIMADA ; Kosuke YOSHIHARA ; Terumi TANIGAWA ; Hiroyuki NOMURA ; Junzo HAMANISHI ; Satoe FUJIWARA ; Hiroshi TANABE ; Hiroaki KAJIYAMA ; Masaki MANDAI ; Daisuke AOKI ; Takayuki ENOMOTO ; Aikou OKAMOTO
Journal of Gynecologic Oncology 2023;34(3):e62-
The development of new treatments for gynecological malignancies has been conducted mainly through collaborative international phase III trials led by the United States and Europe. The survival outcomes of many gynecological malignancies have greatly improved as a result. Recent large-scale genome-wide association studies have revealed that drug efficacy and adverse event profiles are not always uniform. Thus, it is important to validate new treatment options in each country to safely and efficiently provide newly developed treatment options to patients with gynecological malignancies. The Japanese Gynecologic Oncology Group (JGOG) is conducting 5 cohort studies (JGOG 3026, 3027, 3028, 3030, and 3031) to establish real-world data (RWD) of poly(ADP-ribose) polymerase (PARP) inhibitor use in patients with advanced or recurrent epithelial ovarian cancer. The RWD constructed will be used to provide newly developed PARP inhibitors for women with advanced or recurrent ovarian cancer in a safer and more efficient manner as well as to develop further treatment options. In 2022, The JGOG, Korean Gynecologic Oncology Group, Chinese Gynecologic Cancer Society, and Taiwanese Gynecologic Oncology Group established the East Asian Gynecologic Oncology Trial Group to collaborate with East Asian countries in clinical research on gynecologic malignancies and disseminate new knowledge on gynecologic malignancies from Asia. The JGOG will conduct a collaborative integrated analysis of the RWD generated from Asian countries and disseminate real-world clinical knowledge regarding new treatment options that have been clinically implemented.
4.Mucosal and Submucosal Thickening of Esophageal Wall Is a Promising Factor in the Development of Symptoms in Eosinophilic Esophagitis
Yugo SUZUKI ; Yorinari OCHIAI ; Atsuko HOSOI ; Takayuki OKAMURA ; Junnosuke HAYASAKA ; Yutaka MITSUNAGA ; Masami TANAKA ; Hiroyuki ODAGIRI ; Kosuke NOMURA ; Satoshi YAMASHITA ; Akira MATSUI ; Daisuke KIKUCHI ; Kenichi OHASHI ; Shu HOTEYA
Gut and Liver 2024;18(1):50-59
Background/Aims:
Asymptomatic esophageal eosinophilia (aEE) is considered to be a potential precursor of eosinophilic esophagitis (EoE). However, there are few clinical parameters that can be used to evaluate the disease. Therefore, we aimed to clarify the factors involved in the symptoms of EoE by examining the clinicopathological differences between aEE and EoE.
Methods:
We reviewed 41 patients with esophageal eosinophilia who underwent endoscopic ultrasonography and high-resolution manometry. They were divided into the aEE group (n=16) and the EoE group (n=25) using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease score. The patients’ clinicopathological findings were collected and examined.
Results:
The median Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease score was 3.0 in the aEE group and 10.0 in the EoE group. There was no significant difference in patient characteristics, endoscopic findings and pathological findings. The cutoff value for wall thickening was 3.13 mm for the total esophageal wall thickness and 2.30 mm for the thickness from the surface to the muscular layer (total esophageal wall thickness: 84.0% sensitivity, 75.0% specificity; thickness from the surface to the muscular layer: 84.0% sensitivity, 68.7% specificity).The high-resolution manometry study was abnormal in seven patients (43.8%) in the aEE group and in 12 (48.0%) in the EoE group. The contractile front velocity was slower in the EoE group (p=0.026).
Conclusions
The esophageal wall thickening in the lower portion of the esophagus is an important clinical factors related to the symptoms in patients with EoE.